AZD8848 Single Ascending Dose Study

Summary

AZD8848 Single Ascending Dose Study is a clinical trial^[1].

Key Facts

• AZD8848 Single Ascending Dose Study is in the country of United Kingdom^[2].
• AZD8848 Single Ascending Dose Study's instance of is recorded as clinical trial^[3].
• AZD8848 Single Ascending Dose Study's start time is recorded as +2012-05-31T00:00:00Z^[4].
• AZD8848 Single Ascending Dose Study's end time is recorded as +2014-07-31T00:00:00Z^[5].
• AZD8848 Single Ascending Dose Study's sponsor is recorded as AstraZeneca^[6].
• AZD8848 Single Ascending Dose Study's main subject is recorded as safety^[7].
• AZD8848 Single Ascending Dose Study's main subject is recorded as tolerability^[8].
• AZD8848 Single Ascending Dose Study's number of participants is recorded as {'unit': '1', 'amount': '+47'}^[9].
• AZD8848 Single Ascending Dose Study's title is recorded as A Double-blind, Placebo-controlled, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD8848 in Healthy Subjects^[10].
• AZD8848 Single Ascending Dose Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[11].
• AZD8848 Single Ascending Dose Study's ClinicalTrials.gov ID is recorded as NCT01560234^[12].
• AZD8848 Single Ascending Dose Study's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+50'}^[13].
• AZD8848 Single Ascending Dose Study's research intervention is recorded as adenosine^[14].
• AZD8848 Single Ascending Dose Study's clinical trial phase is recorded as phase I clinical trial^[15].
• AZD8848 Single Ascending Dose Study's research subject recruitment status is recorded as completed^[16].
• AZD8848 Single Ascending Dose Study's study type is recorded as interventional study^[17].